Announcements Trials
Browse Landscape

Phase

Phase 3 13Phase 1 6Phase 2 3Phase 2/3 2Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 27Neoplasms 22Breast Neoplasms 20Neoplasm Metastasis 18Colorectal Neoplasms 16Stomach Neoplasms 15Recurrence 15Prostatic Neoplasms 15Carcinoma, Hepatocellular 12Pancreatic Neoplasms 11Ovarian Neoplasms 11Head and Neck Neoplasms 11Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 10Leukemia, Myeloid, Acute 10Myasthenia Gravis 9Melanoma 9Urinary Bladder Neoplasms 8Lymphoma, Large B-Cell, Diffuse 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Lymphoma, Follicular 6Liver Neoplasms 6Cholangiocarcinoma 6Carcinoma, Transitional Cell 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia 5

Interventions

tucatinib 1pertuzumab 1Trastuzumab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × HER2-positive Breast Cancer × Clear all
NCT07413939 2026-06-10

BREnnA

Hoffmann-La Roche

Phase 2/3 Recruiting
650 enrolled
Breast

HER2-positive Breast Cancer

NCT06891833 2025-10-02

A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2/3 Recruiting
120 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡